BACKGROUND: We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH). METHODS: We conducted a double-blind, randomized, placebo-controlled, multicenter, phase 3 trial. Patients received either placebo or eculizumab intravenously; eculizumab was given at a dose of 600 mg weekly for 4 weeks, followed 1 week later by a 900-mg dose and then 900 mg every other week through week 26. The two primary end points were the stabilization of hemoglobin levels and the number of units of packed red cells transfused. Biochemical indicators of intravascular hemolysis and the patients' quality of life were also assessed. RESULTS:Eighty-seven patients underwent randomization. Stabilization of hemoglobin levels in the absence of transfusions was achieved in 49% (21 of 43) of the patients assigned to eculizumab and none (0 of 44) of those assigned to placebo (P<0.001). During the study, a median of 0 units of packed red cells was administered in the eculizumab group, as compared with 10 units in the placebo group (P<0.001). Eculizumab reduced intravascular hemolysis, as shown by the 85.8% lower median area under the curve for lactate dehydrogenase plotted against time (in days) in the eculizumab group, as compared with the placebo group (58,587 vs. 411,822 U per liter; P<0.001). Clinically significant improvements were also found in the quality of life, as measured by scores on the Functional Assessment of Chronic Illness Therapy-Fatigue instrument (P<0.001) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Of the 87 patients, 4 in the eculizumab group and 9 in the placebo group had serious adverse events, none of which were considered to be treatment-related; all these patients recovered without sequelae. CONCLUSIONS:Eculizumab is an effective therapy for PNH. 2006Massachusetts Medical Society
RCT Entities:
BACKGROUND: We tested the safety and efficacy of eculizumab, a humanized monoclonal antibody against terminal complement protein C5 that inhibits terminal complement activation, in patients with paroxysmal nocturnal hemoglobinuria (PNH). METHODS: We conducted a double-blind, randomized, placebo-controlled, multicenter, phase 3 trial. Patients received either placebo or eculizumab intravenously; eculizumab was given at a dose of 600 mg weekly for 4 weeks, followed 1 week later by a 900-mg dose and then 900 mg every other week through week 26. The two primary end points were the stabilization of hemoglobin levels and the number of units of packed red cells transfused. Biochemical indicators of intravascular hemolysis and the patients' quality of life were also assessed. RESULTS: Eighty-seven patients underwent randomization. Stabilization of hemoglobin levels in the absence of transfusions was achieved in 49% (21 of 43) of the patients assigned to eculizumab and none (0 of 44) of those assigned to placebo (P<0.001). During the study, a median of 0 units of packed red cells was administered in the eculizumab group, as compared with 10 units in the placebo group (P<0.001). Eculizumab reduced intravascular hemolysis, as shown by the 85.8% lower median area under the curve for lactate dehydrogenase plotted against time (in days) in the eculizumab group, as compared with the placebo group (58,587 vs. 411,822 U per liter; P<0.001). Clinically significant improvements were also found in the quality of life, as measured by scores on the Functional Assessment of Chronic Illness Therapy-Fatigue instrument (P<0.001) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Of the 87 patients, 4 in the eculizumab group and 9 in the placebo group had serious adverse events, none of which were considered to be treatment-related; all these patients recovered without sequelae. CONCLUSIONS:Eculizumab is an effective therapy for PNH. 2006 Massachusetts Medical Society
Authors: Jong Wook Lee; Flore Sicre de Fontbrune; Lily Wong Lee Lee; Viviani Pessoa; Sandra Gualandro; Wolfgang Füreder; Vadim Ptushkin; Scott T Rottinghaus; Lori Volles; Lori Shafner; Rasha Aguzzi; Rajendra Pradhan; Hubert Schrezenmeier; Anita Hill Journal: Blood Date: 2018-12-03 Impact factor: 22.113
Authors: Austin G Kulasekararaj; Anita Hill; Scott T Rottinghaus; Saskia Langemeijer; Richard Wells; F Ataulfo Gonzalez-Fernandez; Anna Gaya; Jong Wook Lee; Emilio Ojeda Gutierrez; Caroline I Piatek; Jeff Szer; Antonio Risitano; Shinji Nakao; Eric Bachman; Lori Shafner; Andrew I Damokosh; Stephan Ortiz; Alexander Röth; Regis Peffault de Latour Journal: Blood Date: 2018-12-03 Impact factor: 22.113
Authors: Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; Antonio M Risitano; John D Lambris Journal: Semin Hematol Date: 2018-02-14 Impact factor: 3.851
Authors: Zohar Yehoshua; Carlos Alexandre de Amorim Garcia Filho; Renata Portella Nunes; Giovanni Gregori; Fernando M Penha; Andrew A Moshfeghi; Kang Zhang; Srinivas Sadda; William Feuer; Philip J Rosenfeld Journal: Ophthalmology Date: 2013-11-26 Impact factor: 12.079
Authors: Stella Santarone; Andrea Bacigalupo; Antonio M Risitano; Elena Tagliaferri; Erminia Di Bartolomeo; Anna Paola Iori; Alessandro Rambaldi; Emanuele Angelucci; Alessandra Spagnoli; Federico Papineschi; Stefania Tamiazzo; Marta Di Nicola; Paolo Di Bartolomeo Journal: Haematologica Date: 2009-12-08 Impact factor: 9.941